The estimated Net Worth of Jean Yves Nothias is at least $413 mil dollars as of 7 May 2014. Jean Nothias owns over 50,000 units of Scynexis Inc stock worth over $413,108 and over the last 11 years he sold SCYX stock worth over $0. In addition, he makes $0 as Director at Scynexis Inc.
Jean has made over 1 trades of the Scynexis Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 50,000 units of SCYX stock worth $500,000 on 7 May 2014.
The largest trade he's ever made was buying 50,000 units of Scynexis Inc stock on 7 May 2014 worth over $500,000. On average, Jean trades about 8,333 units every 0 days since 2014. As of 7 May 2014 he still owns at least 295,077 units of Scynexis Inc stock.
You can see the complete history of Jean Nothias stock trades at the bottom of the page.
Dr. Jean-Yves Nothias, Ph.D. is directors of the Company since August 2000. Since 2012, Dr. Nothias has served as a Director of Genomic Vision SA, a biotechnology company headquartered in Paris. Since 2012, Dr. Nothias is Founder and President of a fund management company Vesale Partners, managing its Biotechnology Fund. From 2000 to 2011, Dr. Nothias served as a Managing Director of SG Asset Management, where he headed the Venture Capital Biotechnology Team. Since 2005, he has served as a director of GenomeQuest Inc., and since 2012 he has served as a director of Bioforce Nanoscience Inc. Since 2009 he has served as an observer of the boards of directors of Somalogic Inc. and Pulmagen Therapeutics. From 1999 to 2000, he was a biotechnology corporate analyst for Oddo & Cie, a French brokerage firm. From 1996 to 1998, he was a sales side biotechnology analyst for Hambrecht & Quist based in Paris. Dr. Nothias holds a thesis in Molecular Biology from Université Pierre & Marie Curie and a master’s degree in management from Université Paris Sorbonne. Because of Dr. Nothias’s extensive biotechnology fund manager and board member experience, we believe he is able to make valuable contributions to our board of directors
Jean Nothias is 54, he's been the Director of Scynexis Inc since 2000. There are 12 older and 3 younger executives at Scynexis Inc. The oldest executive at Scynexis Inc is Patrick Langlois, 70, who is the Director.
Jean's mailing address filed with the SEC is C/O SCYNEXIS, INC.,, 3501 C TRICENTER BOULEVARD, DURHAM, NC, 27713.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado y Marco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: